Gottschalk S - Search Results

1

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S. Ahmed N, et al. Among authors: gottschalk s. Mol Ther. 2009 Oct;17(10):1779-87. doi: 10.1038/mt.2009.133. Epub 2009 Jun 16. Mol Ther. 2009. PMID: 19532139 Free PMC article.

2

Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression.

Gottschalk S, Cristiano RJ, Smith LC, Woo SL. Gottschalk S, et al. Gene Ther. 1994 May;1(3):185-91. Gene Ther. 1994. PMID: 7584080

3

Efficient gene delivery and expression in mammalian cells using DNA coupled with perfringolysin O.

Gottschalk S, Tweten RK, Smith LC, Woo SL. Gottschalk S, et al. Gene Ther. 1995 Sep;2(7):498-503. Gene Ther. 1995. PMID: 7584129

4

A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells.

Gottschalk S, Sparrow JT, Hauer J, Mims MP, Leland FE, Woo SL, Smith LC. Gottschalk S, et al. Gene Ther. 1996 May;3(5):448-57. Gene Ther. 1996. PMID: 9156807

5

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. Gottschalk S, et al. Blood. 2001 Feb 15;97(4):835-43. doi: 10.1182/blood.v97.4.835. Blood. 2001. PMID: 11159505 Free article.

6

Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma.

Gahn B, Siller-Lopez F, Pirooz AD, Yvon E, Gottschalk S, Longnecker R, Brenner MK, Heslop HE, Aguilar-Cordova E, Rooney CM. Gahn B, et al. Among authors: gottschalk s. Int J Cancer. 2001 Sep 1;93(5):706-13. doi: 10.1002/ijc.1396. Int J Cancer. 2001. PMID: 11477583

7

Treatment of Epstein-Barr virus-associated malignancies with specific T cells.

Gottschalk S, Heslop HE, Roon CM. Gottschalk S, et al. Adv Cancer Res. 2002;84:175-201. doi: 10.1016/s0065-230x(02)84006-4. Adv Cancer Res. 2002. PMID: 11883527 Review.

8

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM. Gottschalk S, et al. Blood. 2003 Mar 1;101(5):1905-12. doi: 10.1182/blood-2002-05-1514. Epub 2002 Oct 31. Blood. 2003. PMID: 12411306 Free article.

9

Immune therapy for EBV infections after hemopoietic stem-cell transplant.

Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM. Heslop HE, et al. Among authors: gottschalk s. Cytotherapy. 2002;4(5):433-4. doi: 10.1080/146532402320776071. Cytotherapy. 2002. PMID: 12473214 Review. No abstract available.

10

Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.

Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Sili U, et al. Among authors: gottschalk s. J Immunother. 2003 May-Jun;26(3):241-56. doi: 10.1097/00002371-200305000-00008. J Immunother. 2003. PMID: 12806278

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

389 results

Search Page

Filters